In the present study, we constructed a nomogram that incorporated a two-gene (MEF2C and TRIM15) signature and clinicopathological parameters to assist clinicians in determining the prognosis of individual diffuse-type GC patients. This evidence concerns the gene TRIM15 and gastric cancer.